04:29 PM EDT, 05/09/2024 (MT Newswires) -- Xenon Pharmaceuticals ( XENE ) reported a Q1 net loss late Thursday of $0.62 per diluted share, narrowing from $0.63 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.67.

The company didn't record revenue in the quarter ended March 31 or a year earlier.

Xenon said it ended the quarter with cash and cash equivalents and marketable securities of $885.4 million, sufficient to fund operations into 2027.